Wooters, T. ., Smith, A. ., Pivavarchyk, M. ., Siripurapu, K. ., McIntosh, J. ., Zhang, Z. ., … Dwoskin, L. . (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x

Smith, A. ., Pivavarchyk, M. ., Wooters, T. ., Zhang, Z. ., Zheng, G. ., McIntosh, J. ., … Dwoskin, L. . (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)

Dwoskin, L. ., Pivavarchyk, M. ., Joyce, B. ., Neugebauer, N. ., Zheng, G. ., Zhang, Z. ., … Crooks, P. . Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebraska Symposium on Motivation. Nebraska Symposium on Motivation, 55, 31-63. https://doi.org/10.1007/978-0-387-78748-0_4 (Original work published 2009)

Beckmann, J. ., Meyer, A. ., Pivavarchyk, M. ., Horton, D. ., Zheng, G. ., Smith, A. ., … Dwoskin, L. . (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4